Christopher Hoimes, DO

Publications

Hoimes, Christopher J., Jens Bedke, Yohann Loriot, Hiroyuki Nishiyama, Xiao Fang, Ritesh S. Kataria, Blanca Homet Moreno, and Matt D. Galsky. “KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).” In Journal of Clinical Oncology, 39:TPS4587–TPS4587. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps4587.

Full Text

Friedlander, Terence W., Matthew I. Milowsky, Mehmet Asim Bilen, Sandy Srinivas, Rana R. McKay, Thomas W. Flaig, Christopher J. Hoimes, et al. “Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).” In Journal of Clinical Oncology, 39:4528–4528. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4528.

Full Text

Pal, Sumanta K., Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Wang, et al. “A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.” In Journal of Clinical Oncology, 39:4507–4507. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4507.

Full Text

Esagian, Stepan M., Ali Raza Khaki, Lucia Carril-Ajuria, Joseph J. Park, Mehmet Asim Bilen, Tyler Francis Stewart, Victor Sacristan Santos, et al. “Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.” In Journal of Clinical Oncology, 39:406–406. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.406.

Full Text

Wang, Xinning, Aditi Shirke, Ethan Walker, Rongcan Sun, Gopolakrishnan Ramamurthy, Jing Wang, Lingpeng Shan, et al. “Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.” Cancers (Basel) 13, no. 3 (January 22, 2021). https://doi.org/10.3390/cancers13030417.

PMID
33499427
Full Text

Nelson, A. A., R. J. Cronk, E. A. Lemke, A. Szabo, A. R. Khaki, L. N. Diamantopoulos, P. Grivas, et al. “Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.” Bladder Cancer 7, no. 1 (January 1, 2021): 33–42. https://doi.org/10.3233/BLC-200377.

Full Text

Rosenberg, J. E., T. W. Flaig, T. W. Friedlander, M. I. Milowsky, S. Srinivas, D. P. Petrylak, J. R. Merchan, et al. “First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC).” In Swiss Medical Weekly, 26S-27S, 2020.

Scholars@Duke

Vaishampayan, U. N., T. Elliott, A. G. Omlin, J. N. Graff, C. J. Hoimes, S. T. Tagawa, C. Hwang, et al. “227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199.” In Annals of Oncology, 31:S1330–S1330. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.10.447.

Full Text

Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.

PMID
33115529
Full Text

Shieh, Alice C., Ezgi Guler, David Pfau, Ethan Radzinsky, Daniel A. Smith, Christopher Hoimes, Nikhil H. Ramaiya, and Sree Harsha Tirumani. “Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.” Abdom Radiol (Ny) 45, no. 10 (October 2020): 3028–35. https://doi.org/10.1007/s00261-019-02334-3.

PMID
31754740
Full Text

Pages